The American Journal of Managed Care9m
Varied Types, Levels of Support Needed for Patients With Multiple Myeloma
Information on the disease and treatments, assistance with insurance, and transportation are among the types of support ...
Targeted Oncology13d
MRD Negativity Improves With D-VRd in Newly Diagnosed, Transplant-Eligible Myeloma
Updated findings from the PERSEUS study found that patients with newly diagnosed multiple myeloma benefited from a treatment ...
Cure Today7d
Darzalex Regimen Boosts Rates of MRD Negativity in Newly Diagnosed, Transplant-Eligible Myeloma
A Darzalex-based regiment improved MRD negativity rates while sustaining MRD negativity compared with VRd in patients with ...
Telo Genomics Assessing MRD Status in TELO-DMRD Study
Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “Telo”) a biotech company developing the industry’s leading ...
The American Journal of Managed Care6d
Predicting Survival in CLL: The Power of Measurable Residual Disease
Undetectable measurable residual disease rates can help predict progression-free survival in patients with chronic ...
Is Leukemia Hereditary? Know How Understanding Your Genes Can Help In Treatment
Certain genetic changes, or mutations, can increase the chances of leukemia or blood cancer. According to experts, leukemia, ...
Pharmabiz2d
Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma
Japan’s MHLW accepts for review GSK’s NDA for Blenrep combinations in relapsed/refractory multiple myeloma: London, UK Wednesday, September 18, 2024, 10:00 Hrs [IST] GSK plc a ...
Pharmabiz6d
GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma
GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...